Join
Live feed
·
NEWSReleasevia Quantisnow
Lantern Pharma Inc. logo

Lantern Pharma Achieves Milestone Towards Development Of Molecular Diagnostic For Use In Oncology Clinical Trials For Patient Selection And Stratification With Drug Candidate LP-184; Confirmed PTGR1 As A Key Biomarker That It Intends To Use To Optimize Patient Selection Based On Potential Tumor Sensitivity To The Drug Candidate LP-184

ByQuantisnow·Wall Street's wire, on your screen.
LTRN· Lantern Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LTRN (Lantern Pharma Inc.) and more on Quantisnow.